SARS‐CoV‐2 infection drives the increasingly recognized thrombotic complications in COVID‐19 patients, potentially due to the SARS‐CoV‐2 Spike protein binding to human angiotensin‐converting enzyme 2. This evidence concerns the gene ACE2 and COVID-19.